hydroxyprogesterone heptanoate hydroxyprogesterone heptanoate hydroxyprogesterone heptanoate (ohph), also known as hydroxyprogesterone enanthate (ohpe) and sold under the brand names h.o.p., lutogil a.p., and lutogyl a.p. among others, is a progestin medication used for progestogenic indications. it has been formulated both alone and in together with estrogens, androgens/anabolic steroids, and other progestogens in several combination preparations (brand names tocogestan, trioestrine retard, and triormon depositum). ohph is given by injection into muscle at regular intervals. not to be confused with 17α-hydroxyprogesterone, hydroxyprogesterone acetate, or hydroxyprogesterone caproate. hydroxyprogesterone heptanoateclinical datatrade namesh.o.p, hydroxyprogesterone, lutogil a.p., lutogyl a.p., othersother namesohph; hydroxyprogesterone enanthate; ohpe; 17α-hydroxyprogesterone heptanoate; 17α-hydroxyprogesterone heptylate; 17α-hydroxypregn-4-ene-3,20-dione 17α-heptanoate; 17α-heptyloylpregn-4-ene-3,20-dioneroutes ofadministrationintramuscular injectiondrug classprogestogen; progestin; progestogen esteratc codeg03da03 (who) identifiers iupac name phenanthren-17-yl] heptanoate cas number4596-16-1 1079269-78-5pubchem cid94296chemspider85099uniihgn17rx8k8comptox dashboard (epa)dtxsid70196666 echa infocard100.022.724 chemical and physical dataformulac28h42o4molar mass442.640 g·mol−13d model (jsmol)interactive image smiles ccccccc(=o)oc1(ccc2c1(ccc3c2ccc4=cc(=o)ccc34c)c)c(=o)c inchi inchi=1s/c28h42o4/c1-5-6-7-8-9-25(31)32-28(19(2)29)17-14-24-22-11-10-20-18-21(30)12-15-26(20,3)23(22)13-16-27(24,28)4/h18,22-24h,5-17h2,1-4h3/t22-,23+,24+,26+,27+,28+/m1/s1key:nkjyzywcgksmsv-bdpsoknusa-n ohph is a progestin, or a synthetic progestogen, and hence is an agonist of the progesterone receptor, the biological target of progestogens like progesterone. it appears to have similar pharmacology to that of the closely related medication hydroxyprogesterone caproate (ohpc). ohph was first described by 1954 and was introduced for medical use by 1957. it has been used clinically in france and monaco in the past but is no longer marketed. medical uses ohph is a progestogen and was used in situations in which progestogens were indicated. available forms ohph was provided as a 125 mg/1 ml oil solution for use by intramuscular injection. in addition to single-drug preparations, ohph has also been used in a number of multi-drug formulations. it was used in tocogestan, a combination of 50 mg progesterone, 200 mg ohph, and 250 mg α-tocopherol palmitate (vitamin e) in oil solution for use by intramuscular injection. it was also used in triormon depositum (estradiol dibutyrate, testosterone caproate, and ohph) and trioestrine retard (estradiol diundecylate, testosterone cyclohexylpropionate, and ohph). ohph was a component of the experimental preparation trophobolene (or trophoboline), which also contained estrapronicate (estradiol nicotinate propionate) and nandrolone undecanoate, as well. pharmacology pharmacodynamics ohph is a progestin, or a synthetic progestogen, and hence is an agonist of the progesterone receptor, the biological target of progestogens like progesterone. the progestogenic potency of ohph in the uterus is equal to or greater than that of progesterone when administered by subcutaneous injection in animals. its potency in animals likewise appears to be similar to that of hydroxyprogesterone caproate. pharmacokinetics ohph shows a pronounced depot effect when administered by subcutaneous injection in animals, similarly to the closely related medication hydroxyprogesterone caproate. the oral activity of ohph in animals does not appear to have been assessed. chemistry